EyePoint Pharmaceuticals Inc EYPT reported Q1 revenues of $7.68 million, down from $9.3 million a year ago but slightly beating the $7.43 million consensus.
Operating expenses reached $29.2 million compared with $27.6 million a year ago, primarily driven by continued investment in R&D for EYP-1901 development, offset by a reduction in sales and marketing spend for DEXYCU.
Net product revenue for Yutiq was $7.4 million, up 60% Y/Y, with a customer demand of approximately 930 units.
The company reported a smaller-than-expected EPS loss of $(0.56), beating the consensus of $(0.68).
Cash, cash equivalents, and investments of $122.5 million will provide a cash runway into the second half of 2024.
Pipeline Update:
- The company completed enrollment in an oversubscribed Phase 2 DAVIO 2 trial of EYP-1901 for maintenance treatment for wet AMD in March 2023. Topline data remain on track for Q4 of 2023.
- Enrollment ahead of schedule in the Phase 2 PAVIA trial of EYP-1901 in non-proliferative diabetic retinopathy. The trial size was reduced based on robust clinical evidence and proof-of-concept for vorolanib and EYP-1901.
- Plans to initiate a Phase 2 trial evaluating EYP-1901 in diabetic macular edema in Q1 of 2024 remain on track.
Price Action: EYPT shares are up 19.3% at $7.74 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.